This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Reviewing the top-line results of EyePoint's Phase II DAVIO 2 trial of EYP-1901 for wet-AMD

Ticker(s): EYPT

Who's the expert?

Institution: Johns Hopkins

  • Professor and Chairman of Ophthalmology at Johns Hopkins Bayview Medical Center
  • Manages 40 patients per week with geographic atrophy
  • Teaches and conducts clinical research that has led to advances in the treatment of complex retinal detachments, vitreo-retinal complications of refractive surgery, diabetic retinopathy and age-related macular degeneration 

Interview Questions
Q1.

Describe your background and practice setting

Added By: ben_admin
Q2.

What is your current treatment algorithm for patients with wet-AMD

Added By: ben_admin
Q3.

What are your thoughts on the potential of a sustained release delivery system for wet-AMD management?

Added By: ben_admin
Q4.

What are your thoughts on the recent data for EYP-1901?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.